These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12176401)

  • 1. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR
    Transplant Proc; 2002 Aug; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract]   [Full Text] [Related]  

  • 2. The interleukin-2 inhibitors and their role in low-toxicity regimens.
    Nashan B
    Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of newer monoclonal antibodies in renal transplantation.
    Vincenti F
    Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
    Pascual J; Marcén R; Ortuño J
    Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
    [No Abstract]   [Full Text] [Related]  

  • 5. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation.
    Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber AO
    Transplant Proc; 2001; 33(1-2):1701-3. PubMed ID: 11267477
    [No Abstract]   [Full Text] [Related]  

  • 6. Daclizumab.
    Mottershead M; Neuberger J
    Expert Opin Biol Ther; 2007 Oct; 7(10):1583-96. PubMed ID: 17916050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
    Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
    [No Abstract]   [Full Text] [Related]  

  • 8. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
    Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
    Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
    [No Abstract]   [Full Text] [Related]  

  • 9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP; Nampoory MR; Johny KV; Costandi JN; Abdulhalim M; El-Reshaid W; Al-Muzairai I; Ninan VT; Samhan M; Al-Mousawi M
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of antibodies against the IL-2 receptor in transplantation.
    Waldmann TA; O'Shea J
    Curr Opin Immunol; 1998 Oct; 10(5):507-12. PubMed ID: 9794841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of anti-interleukin-2 receptor antibodies in pediatric liver transplantation.
    Kelly DA
    Pediatr Transplant; 2001 Dec; 5(6):386-9. PubMed ID: 11737761
    [No Abstract]   [Full Text] [Related]  

  • 14. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F
    Transplant Proc; 1999 Sep; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of daclizumab (zenapax) on prevention of acute rejection of renal transplantation.
    Poorrezagholi F; Einollahi B; Firoozan A; Nafar M; Yadegari H; Moghaddam SM; Simforoosh N; Basiri A; Farhangi S
    Transplant Proc; 2003 Nov; 35(7):2735-6. PubMed ID: 14612098
    [No Abstract]   [Full Text] [Related]  

  • 16. Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups.
    Vincenti F; Nashan B; Light S
    Transplant Proc; 1998 Aug; 30(5):2155-8. PubMed ID: 9723424
    [No Abstract]   [Full Text] [Related]  

  • 17. [Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].
    ter Meulen CG; Hilbrands LB; van Riemsdijk-van Overbeeke IC; Hené RJ; Christiaans MH; Hoitsma AJ
    Ned Tijdschr Geneeskd; 2000 Dec; 144(50):2396-400. PubMed ID: 11145094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab to prevent acute rejection in renal transplantation.
    Abramowicz D
    N Engl J Med; 1998 Jun; 338(23):1700-1. PubMed ID: 9616069
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Basiliximab Versus Daclizumab in Kidney Transplantation: A Meta-Analysis.
    Sun ZJ; Du X; Su LL; Zhang XD; Wang W
    Transplant Proc; 2015 Oct; 47(8):2439-45. PubMed ID: 26518947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.